Hexarelin Acetate

Overview

Hexarelin (Examorelin) is a synthetic growth-hormone-releasing hexapeptide — a structurally optimized descendant of GHRP-6 and one of the most potent peptidic GH secretagogues characterized. It acts at the growth-hormone-secretagogue receptor (GHS-R1a, the ghrelin receptor) to trigger pulsatile pituitary GH release, and is separately studied for a partly GH-independent action at the CD36 scavenger receptor that underlies its cardiovascular research interest. PeptideXpo supplies the acetate salt used across GH-axis research. Hexarelin acetate ships as a lyophilized powder at ≥ 98% HPLC. Among the GHRP-family tools it stands out for high potency and, in the published literature, for faster receptor desensitization on continuous exposure than the milder secretagogues — buyers designing repeat-dose research should account for that tachyphylaxis when comparing it against GHRP-2, GHRP-6, or ipamorelin. Prepare in bacteriostatic or sterile water, aliquot, and store frozen. Standard 2 mg and 5 mg fills cover common research scales. Supplied as a research reference material only.

Who buys this, and why

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

140703-51-1

Molecular Formula

C47H58N12O6

Molecular Weight

887.0 Da (free base)

Sequence

His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

2 mg – 5 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 55 minutes

MOQ

On request

Lead time

7–14 days

Storage

2–8°C, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• HPLC Chromatogram
• Mass-spec identity (ESI-MS)
• Counter-ion (acetate vs TFA)
• Sterile-fill release pack (sterility, CCI, fill-weight)
• Bacterial endotoxin (LAL, USP <85>)
• Stability data on request
• SDS / MSDS

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

1. Deghenghi R, Cananzi MM, Torsello A, Battisti C, Müller EE, Locatelli V. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 1994;54(18):1321-1328.
2. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab. 1994;78(3):693-698.
3. Torsello A, Grilli R, Luoni M, Guidi M, Ghigo MC, Wehrenberg WB, Deghenghi R, Müller EE, Locatelli V. Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat. Eur J Endocrinol. 1996;135(4):481-488.
4. Loche S, Cambiaso P, Merola B, Colao A, Faedda A, Imbimbo BP, Deghenghi R, Lombardi G, Cappa M. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency. J Clin Endocrinol Metab. 1995;80(9):2692-2696.
5. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8(Suppl B):141-143.
6. Bodart V, Bouchard JF, McNicoll N, Escher E, Carrière P, Ghigo E, Sejlitz T, Sirois MG, Lamontagne D, Ong H. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res. 1999;85(9):796-802.

Frequently asked questions